Marina Díaz‐Beyá

Josep Carreras Leukaemia Research Institute — Spain

Medicine · Health Sciences

23h-index2.1kcitations158works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(100), Chronic Myeloid Leukemia Treatments(34), Myeloproliferative Neoplasms: Diagnosis and Treatment(32), Acute Lymphoblastic Leukemia research(29), Chronic Lymphocytic Leukemia Research(19)

Publications158 total

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group
Blood·2025Open Access
Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults
Blood·2025
Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers
Blood·2025Open Access
Beyond TP53: Molecular IPSS-genes multihit status revisited
Blood·2025Open Access
Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study
Blood·2025
The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms
Blood·2025Open Access
Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia
Blood·2025
Efficacy and safety of CPX-351 in high-risk Acute Myeloid Leukemia
Blood·2025Open Access
Better discriminative capacity of blast and blast-mol scores in chronic myelomonocytic leukemia (CMML)
Blood·2025Open Access
Management guide for treatment with venetoclax and azacitidine in patients with acute myeloid leukemia ineligible for intensive chemotherapy
Revista Sangre (ENG)·2025Open Access
A COMPARISON OF PROGNOSTIC VARIABLES AND CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED AND 4738 WITH PRIMARY MDS INCLUDING THE INFLUENCE OF TREATMENT IN MDS-PHASE
Leukemia Research·2025
Guía de manejo del tratamiento con venetoclax y azacitidina de pacientes con leucemia mieloblástica aguda no tributarios de quimioterapia intensiva
Revista Sangre·2025Open Access
Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain
Annals of Hematology·2025· 1 citedOpen Access
CAR-T cell therapy for cancer: current challenges and future directions
Signal Transduction and Targeted Therapy·2025· 89 citedOpen Access
CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia
Journal of Hematology & Oncology·2025· 7 citedOpen Access
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations
Blood Cancer Journal·2025· 1 citedOpen Access
Genetic evolution and relapse‐associated mutations in adult T‐cell acute lymphoblastic leukemia patients treated in PETHEMA trials
HemaSphere·2025Open Access
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study
Experimental Hematology and Oncology·2025· 3 citedOpen Access
Rapid Screening and Monitoring of UBA1 Mutations in VEXAS Syndrome
Journal of Molecular Diagnostics·2025· 2 cited
Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia
Haematologica·2025· 1 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Jordi Esteve(32), Mar Tormo(15), Marta Pratcorona(13), Marı́a Rozman(12), Josep Nomdedéu(11), Josep‐María Ribera(10), Jorge Sierra(10), Francesca Guijarro(10), Sandra Castaño‐Díez(10), Salut Brunet(9), Dolors Colomer(9), Montserrat Torrebadell(8), Ruth M. Risueño(8), Mònica López‐Guerra(8), Olga Salamero(7), Meritxell Nomdedéu(7), Alfons Navarro(7), Álex Bataller(7), Montserrat Arnán(7), Susana Vives(7)